Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
281 questions in 50 reviews · Gynaecological, Neuro-oncology and Orphan Cancer
current versionsNo studies 281 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Neuronavigation image‐guided surgery vs standard surgery Adverse events · high‐grade glioma Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs vitamin K antagonist (VKA) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs low molecular weight heparin (LMWH) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Vitamin K antagonist (VKA) vs low molecular weight heparin (LMWH) Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) All‐cause mortality ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) Symptomatic deep vein thrombosis ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs direct oral anticoagulants (DOAC) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Aspirin (ASA) vs vitamin K antagonist (VKA) Major bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents (2021) · Cochrane | no estimate extracted | NR | No studies |
Green tea extract supplementation vs placebo Quality of life · adults (aged at least 18 years) Green tea (Camellia sinensis) for the prevention of cancer (2020) · Cochrane | no estimate extracted | NR | No studies |
Hormone replacement therapy (HRT) vs no HRT Incidence of gallstones Hormone replacement therapy after surgery for epithelial ovarian cancer (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Overall survivala · adult women with symptoms of endometrial cancer Health education interventions to promote early presentation and referral for women with symptoms of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Disease‐free survivalb · adult women with symptoms of endometrial cancer Health education interventions to promote early presentation and referral for women with symptoms of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Delayed referralc · adult women with symptoms of endometrial cancer Health education interventions to promote early presentation and referral for women with symptoms of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Delayed presentationd · adult women with symptoms of endometrial cancer Health education interventions to promote early presentation and referral for women with symptoms of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Referral time (days)e · adult women with symptoms of endometrial cancer Health education interventions to promote early presentation and referral for women with symptoms of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Presentation time (days)f · adult women with symptoms of endometrial cancer Health education interventions to promote early presentation and referral for women with symptoms of… (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR RIN_CRT vs CRT · elderly people with newly diagnosed glioblastoma Interventions: one treatment option Comparison: an alternative… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR TTF_AC vs CRT · elderly people with newly diagnosed glioblastoma Interventions: one treatment option Comparison: an alternative… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR IRI_BEV_RT vs CRT · elderly people with newly diagnosed glioblastoma Interventions: one treatment option Comparison: an alternative… Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR RT vs supportive care only · elderly people with newly diagnosed glioblastoma Treatment of newly diagnosed glioblastoma in the elderly: a network meta‐analysis (2020) · Cochrane | no estimate extracted | NR | No studies |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Improvement of ascites‐related symptoms · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Participant satisfaction · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Caregiver satisfaction · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Abdominal paracentesis and intraperitoneal infusion of catumaxomab vs abdominal paracentesis alone Cost‐effectiveness · women with malignant ascites Management of drainage for malignant ascites in gynaecological cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Robot‐assisted surgery vs conventional laparoscopic surgery Blood transfusions · gynaecology Robot‐assisted surgery in gynaecology (2019) · Cochrane | no estimate extracted | NR | No studies |
mTOR inhibitors vs chemotherapy/hormone therapy Quality of life ‐ not reported · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Caregiver physical functioning – not measured · caregiver well‐being Interventions to help support caregivers of people with a brain or spinal cord tumour (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Progression free survival · adults with glioblastoma Interval brain imaging for adults with cerebral glioma (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Anxiety · adults with glioblastoma Interval brain imaging for adults with cerebral glioma (2019) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life · adults with glioblastoma Interval brain imaging for adults with cerebral glioma (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine vs three doses of HPV vaccine Clinical and harms outcomes* · 9‐ to 15‐year‐old females Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval Invasive cervical, vaginal, vulval, anal, or penile cancer · 9‐ to 14‐year‐old females and males Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval High‐grade cervical, vulval, vaginal, penile, or anal intraepithelial neoplasia · 9‐ to 14‐year‐old females and males Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval Overall systemic events and general symptoms · 9‐ to 14‐year‐old females and males Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Three doses HPV vaccine vs control Invasive anal or penile cancer · 10‐ to 26‐year‐old males Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine vs three doses of HPV vaccine High‐grade cervical intraepithelial neoplasia, adenocarcinoma in situ, and cervical cancer · 9‐ to 15‐year‐old females Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine vs three doses of HPV vaccine High‐grade cervical, vulval, and vaginal disease · 9‐ to 15‐year‐old females Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine vs three doses of HPV vaccine Overall local/injection site adverse events · 9‐ to 15‐year‐old females Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine vs three doses of HPV vaccine Overall systemic events and general symptoms · 9‐ to 15‐year‐old females Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Two doses of HPV vaccine with longer interval vs two doses of HPV vaccine with shorter interval Clinical and harms outcomes* · 9‐ to 14‐year‐old females and males Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of… (2019) · Cochrane | no estimate extracted | NR | No studies |
Hyperbaric oxygen vs air breathing Quality of life ‐ not reported · People undergoing radiotherapy for uterine cervical cancer Hyperbaric oxygenation for tumour sensitisation to radiotherapy (2018) · Cochrane | no estimate extracted | NR | No studies |
Hyperbaric oxygen vs air breathing Failure of local tumour control ‐ not reported · People with any one of a mixed group of cancers Hyperbaric oxygenation for tumour sensitisation to radiotherapy (2018) · Cochrane | no estimate extracted | NR | No studies |
Hyperbaric oxygen vs air breathing Local recurrence ‐ not reported · People with any one of a mixed group of cancers Hyperbaric oxygenation for tumour sensitisation to radiotherapy (2018) · Cochrane | no estimate extracted | NR | No studies |
Hyperbaric oxygen vs air breathing Quality of life ‐ not reported · People with any one of a mixed group of cancers Hyperbaric oxygenation for tumour sensitisation to radiotherapy (2018) · Cochrane | no estimate extracted | NR | No studies |
Hyperbaric oxygen vs air breathing to enhance the effectiveness of radiotherapy Quality of life ‐ not reported · People undergoing radiation therapy for head and neck cancer Hyperbaric oxygenation for tumour sensitisation to radiotherapy (2018) · Cochrane | no estimate extracted | NR | No studies |
Hyperbaric oxygen vs air breathing Failure of local tumour control ‐ not reported · People undergoing radiotherapy for uterine cervical cancer Hyperbaric oxygenation for tumour sensitisation to radiotherapy (2018) · Cochrane | no estimate extracted | NR | No studies |